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In the 1930s the structure of steroids was discovered, together with the notion that high dose oestrogens, progesterones and androgens inhibited ovulation.1 Naturally, this has led 
to the development of oral hormonal contraceptives. This 
can be considered to be one of the epochal events of the 20th 
century since their direct and indirect effects on hormonal and 
metabolic pathways have shaped a new era of pharmacological 
control.
This research opened the doors to experimentation and 
development into an ideal oral contraceptive pill (OCP). The 
1950s showed the introduction and marketing of the first 
combined OCP, Enovid® 10mg (Searle) (9.85 mg norethynodrel 
and 150 µg mestranol) for menstrual disorders. Following 
further stage 4 trials, the dose was decreased form a 10mg to a 
2.5mg dose.1 
Further studies and understanding of the steroid cycle 
and products led to the discovery of new progestogens and 
estrogens. This in turn led to the development of newer 
generation combined contraceptive pills.
The evolution of the oral contraceptive pill ranged from 
changes in formulation, dosing, phases of action and active 
ingredient. The 1980s showed the introduction of the triphasic 
pills, whilst the 1990s showed the introduction of lower 
dose ethinylestradiol oral contraceptives focusing mainly on 
reduction of adverse side effects and enhancing tolerability 
to the combined oral contraceptive.1 In view of the decreased 
dosage and the 21/7 day regimes, this led to an increase in 
episodes of spotting or intracyclic bleeding leading to some 
women to shy away from the oral contraceptive or be less 
compliant, resulting in an increased number of unexpected 
pregnancies.2,3
The subsequent important milestone in the combined 
oral contraceptive pill development is the introduction of the 
24/4 and 26/2 regimes.3,4,5 The shortening of the hormone-
free interval resulted in further suppression of follicles 
and a decrease in spotting intervals, thus leading to better 
compliance which in turn translated in a decrease of unintended 
pregnancies.4
The various studies which have been conducted during the 
five years following the introduction of COCPs such as 3mg 
drosperenone and 0.02mg ethinylestradiol, 2.5mg nomegestrol 
and 1.5mg estradiol, and quadriphasic COCPs having a 24/4 
regime have evidenced better compliance and tolerability.4,6,7 
Benefits of a shorter hormone-free interval are that women do 
not experience hormonal withdrawal symptoms as intensely 
as women using 21/7 regimens. It has been demonstrated that 
women with a history of pre-menstrual dysphoric disorder 
experienced less premenstrual symptoms such as mood swings, 
water retention, bloating, headaches, acne and weight gain 
while taking a regimen of ethinyl-estradiol and droperinone/
normogestrol for a minimum of 24 out of 28 days.7,8 These 
benefits may translate to better user compliance and ultimately 
could reduce unintended pregnancy as shown in figure 1.9
In 2008, an ovulation inhibition study10 researched the effects 
of “missed pills” by replacement of the first three pills with a 
placebo after a completed cycle. It compared a 24-day with a 
21-day regimen of 3mg drospirenone/0.02mg ethinyl estradiol. 
Results showed a suppression of ovarian activity, resulting in 
decreased hormonal fluctuations. This was substantially more 
pronounced in the regimen of 24 days of active tablets followed 
by 4 days of inactive tablets than the regimen of 21 days of active 
tablets followed by 7 days of inactive tablets.9 This means that 
the  24/4 regime is less prone to fluctuations especially if the 
patient misses a tablet.
Debate regarding the oral contraceptive pill still remains 
open with new regimes improving on the existing, in a struggle 
to create the “perfect” contraceptive with good tolerability and 
compliance with the least side-effects.
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Figure 1: Incidence of unintended pregnancies compared 
to different regimes of oral contraception. Adopting a 24/4 
regimen of ethinyl-estradiol and droperinone translates in 
maximum protection.9
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